Dosage regime of crinecerfont for treating congenital adrenal hyperplasia in a pediatric subject
AssigneeNeurocrine Biosciences, Inc.
InventorsJean L. Chan, Robert H. Farber
Life of this patent
Estimating the term…
Abstract
Provided are methods of administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, in a pediatric subject having congenital adrenal hyperplasia.
Claims97
A method of administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof,
- as an adjunct to glucocorticoid therapy in a pediatric subject having congenital adrenal hyperplasia (CAH), the method comprising:
- administering to the subject a first amount of Compound A, or a pharmaceutically acceptable salt thereof, for a first period of time, and subsequently administering to the subject a second amount of Compound A, or a pharmaceutically acceptable salt thereof, for a second period of time, wherein the second amount is administered in two doses consisting of a first dose and a second dose wherein the second dose is greater than the first dose.
A method of treating congenital adrenal hyperplasia (CAH) in a pediatric subject already being treated with glucocorticoid therapy, the method comprising:
- administering to the subject a first amount of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof,
- for a first period of time, and subsequently administering to the subject a second amount of Compound A, or a pharmaceutically acceptable salt thereof, for a second period of time, wherein the second amount is administered in two doses consisting of a first dose and a second dose wherein the second dose is greater than the first dose.
A compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine:
- or a pharmaceutically acceptable salt thereof;
- for use in a method of treating congenital adrenal hyperplasia (CAH) in a pediatric subject already being treated with glucocorticoid therapy, the method comprising:
- (1) administering to the subject a first amount of Compound A, or a pharmaceutically acceptable salt thereof, for a first period of time, and
- (2) subsequently administering to the subject a second amount of Compound A, or a pharmaceutically acceptable salt thereof, for a second period of time,
- wherein the second amount is administered in two doses consisting of a first dose and a second dose wherein the second dose is greater than the first dose.
Use of a compound which is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine:
- or a pharmaceutically acceptable salt thereof;
- in the manufacture of a medicament for treating congenital adrenal hyperplasia (CAH) in a pediatric subject already being treated with glucocorticoid therapy, by a method comprising the steps:
- (1) administering to the subject a first amount of Compound A, or a pharmaceutically acceptable salt thereof, for a first period of time, and
- (2) subsequently administering to the subject a second amount of Compound A, or a pharmaceutically acceptable salt thereof, for a second period of time,
- wherein the second amount is administered in two doses consisting of a first dose and a second dose wherein the second dose is greater than the first dose.
Dependencies are inferred from the claim text.